{"id":8819,"date":"2026-09-29T15:57:04","date_gmt":"2026-09-29T12:57:04","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=8819"},"modified":"2026-09-29T16:04:37","modified_gmt":"2026-09-29T13:04:37","slug":"secretome-stm-01-duchenne-thrive-2-clinical-trial","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/tr\/secretome-stm-01-duchenne-thrive-2-clinical-trial\/","title":{"rendered":"STM-01, Duchenne Kas Distrofisi \u0130\u00e7in Faz 2 Klinik \u00c7al\u0131\u015fmas\u0131na Ba\u015flad\u0131"},"content":{"rendered":"<p class=\"wp-block-paragraph\"><strong>Secretome Therapeutics, Duchenne kas distrofisi (DMD) hastalar\u0131nda deneysel tedavisi STM-01&#039;i de\u011ferlendiren Faz 2 klinik \u00e7al\u0131\u015fmas\u0131 THRIVE-2&#039;nin ba\u015flad\u0131\u011f\u0131n\u0131 duyurdu. \u00c7al\u0131\u015fmaya kay\u0131tlar ba\u015flad\u0131 ve ilk kat\u0131l\u0131mc\u0131n\u0131n yak\u0131nda kaydolmas\u0131 bekleniyor.<\/strong><\/p>\n\n\n\n<h3 class=\"wp-block-heading\">THRIVE-2 Nedir?<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">THRIVE-2, \u00e7ok merkezli, \u00e7ok dozlu, a\u00e7\u0131k etiketli bir Faz 2 klinik \u00e7al\u0131\u015fmas\u0131 olarak tasarlanm\u0131\u015ft\u0131r. Ara\u015ft\u0131rmac\u0131lar, DMD hastalar\u0131nda STM-01&#039;in hem g\u00fcvenli\u011fini hem de potansiyel etkinli\u011fini de\u011ferlendireceklerdir.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>\u00c7al\u0131\u015fman\u0131n \u00f6nemli bir \u00f6zelli\u011fi, hem iskelet kas\u0131 hem de kalp fonksiyonuna odaklanmas\u0131d\u0131r.<\/strong> Bu durum \u00f6zellikle DMD&#039;de \u00f6nemlidir \u00e7\u00fcnk\u00fc hastal\u0131k sadece hareketten sorumlu kaslar\u0131 etkilemekle kalmaz. Zamanla kalpte meydana gelen ilerleyici hasar da hastal\u0131\u011f\u0131n \u00f6nemli bir par\u00e7as\u0131 haline gelebilir.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Yap\u0131lan a\u00e7\u0131klamada, DMD&#039;nin s\u00fcrekli kas hasar\u0131, kronik iltihaplanma ve fibrozis i\u00e7eren bir durum oldu\u011fu belirtiliyor. Bu s\u00fcre\u00e7ler, iskelet ve kalp kas\u0131 fonksiyonlar\u0131n\u0131n ilerleyici kayb\u0131na katk\u0131da bulunabilir.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">STM-01 nedir?<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>STM-01, yenido\u011fan kalp k\u00f6k h\u00fccrelerinden (nCPC&#039;ler) elde edilen, ara\u015ft\u0131rma a\u015famas\u0131nda olan bir biyolojik tedavidir.<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">STM-01, eksik olan distrofin proteininin yerini almak \u00fczere \u00f6zel olarak tasarlanmak yerine, farkl\u0131 bir tedavi yakla\u015f\u0131m\u0131 etraf\u0131nda geli\u015ftirilmektedir. <strong>Secretome Therapeutics&#039;ye g\u00f6re, bu tedavinin amac\u0131, Secretome olarak bilinen bu h\u00fccreler taraf\u0131ndan sal\u0131nan fakt\u00f6rlerin rejeneratif aktivitesini kullanmakt\u0131r.<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>\u015eirket, bu do\u011fal olarak olu\u015fan biyoaktif fakt\u00f6rlerin iltihap \u00f6nleyici ve fibroz \u00f6nleyici \u00f6zelliklere sahip oldu\u011funu belirtiyor.<\/strong> Ama\u00e7, kronik iltihaplanma, fibroz ve doku onar\u0131m\u0131 s\u00fcre\u00e7lerinde rol oynayan biyolojik yollar\u0131 etkilemektir.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Basit\u00e7e ifade etmek gerekirse, bu yakla\u015f\u0131m, altta yatan genetik mutasyonu do\u011frudan d\u00fczeltmek yerine, DMD&#039;de devam eden kas ve doku hasar\u0131na katk\u0131da bulunan baz\u0131 biyolojik s\u00fcre\u00e7leri ele almay\u0131 ama\u00e7lamaktad\u0131r.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">\u0130ltihaplanma ve Fibrozis Neden \u00d6nemlidir?<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">DMD, tekrarlayan kas yaralanmalar\u0131na neden olur. Zamanla, hasar g\u00f6rm\u00fc\u015f kas dokusu ya\u011f ve fibrotik doku ile de\u011fi\u015ftirilebilir. Kronik iltihaplanma da bu s\u00fcrece katk\u0131da bulunabilir.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">THRIVE-2 ara\u015ft\u0131rmas\u0131nda yer alan bilim insanlar\u0131na g\u00f6re, iltihaplanma ve fibrozisi hedeflemek, doku hasar\u0131 ve yeniden yap\u0131lanmas\u0131nda rol oynayan \u00f6nemli mekanizmalara \u00e7\u00f6z\u00fcm getirebilir.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Ancak STM-01 halen ara\u015ft\u0131rma a\u015famas\u0131nda olan bir tedavi y\u00f6ntemidir.<\/strong> Klinik \u00f6ncesi bulgular, tedavinin DMD hastalar\u0131nda g\u00fcvenli veya etkili olup olmayaca\u011f\u0131n\u0131 belirleyemez. Faz 2 klinik ara\u015ft\u0131rmalar\u0131n\u0131n amac\u0131, bu sorulara cevap bulmaya yard\u0131mc\u0131 olabilecek insan klinik verilerini toplamakt\u0131r.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Klinik \u00f6ncesi \u00e7al\u0131\u015fmalar ne g\u00f6sterdi?<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Yap\u0131lan a\u00e7\u0131klamada, kar\u015f\u0131la\u015ft\u0131rmal\u0131 preklinik \u00e7al\u0131\u015fmalarda STM-01&#039;in di\u011fer bir\u00e7ok k\u00f6k h\u00fccre yakla\u015f\u0131m\u0131na k\u0131yasla kalp fonksiyonunda daha b\u00fcy\u00fck iyile\u015fmeler ve kalp fibrozunda daha b\u00fcy\u00fck azalmalar sa\u011flad\u0131\u011f\u0131 belirtildi. Bu bulgular, THRIVE-2 \u00e7al\u0131\u015fmas\u0131na kat\u0131lan bir ara\u015ft\u0131rmac\u0131 taraf\u0131ndan dile getirildi.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Bu sonu\u00e7lar daha fazla ara\u015ft\u0131rma i\u00e7in cesaret verici alanlar olu\u015fturmaktad\u0131r, ancak STM-01&#039;in hastalarda ayn\u0131 faydalar\u0131 sa\u011flayaca\u011f\u0131na dair kan\u0131t olarak yorumlanmamal\u0131d\u0131r. Laboratuvar ve klinik \u00f6ncesi bulgular\u0131n insanlar i\u00e7in anlaml\u0131 sonu\u00e7lara d\u00f6n\u00fc\u015f\u00fcp d\u00f6n\u00fc\u015fmeyece\u011fini belirlemek i\u00e7in klinik \u00e7al\u0131\u015fmalar gereklidir.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Bundan sonra ne olacak?<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">THRIVE-2 \u00e7al\u0131\u015fmas\u0131n\u0131n, DMD hastalar\u0131nda STM-01&#039;in g\u00fcvenli\u011fi ve iskelet ve kalp kas\u0131 \u00fczerindeki potansiyel etkileri de dahil olmak \u00fczere, STM-01 hakk\u0131nda ek bilgiler sa\u011flamas\u0131 bekleniyor.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u015eirket, kat\u0131l\u0131mc\u0131 klinik merkezler ve uygunluk kriterleri hakk\u0131ndaki bilgilerin, merkezler kat\u0131l\u0131mc\u0131 kaydetmeye ba\u015flad\u0131k\u00e7a ClinicalTrials.gov arac\u0131l\u0131\u011f\u0131yla payla\u015f\u0131laca\u011f\u0131n\u0131 belirtti.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">ClinicalTrials.gov, ABD Ulusal T\u0131p K\u00fct\u00fcphanesi taraf\u0131ndan y\u00f6netilmekte olup, kay\u0131tl\u0131 klinik \u00e7al\u0131\u015fmalar ve sonu\u00e7lar\u0131 hakk\u0131nda bilgi sa\u011flamaktad\u0131r.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Duchenne kas distrofisi (DMD) toplulu\u011fu i\u00e7in THRIVE-2, iltihaplanma, fibroz ve doku onar\u0131m\u0131na odaklanan bir tedavi stratejisini ara\u015ft\u0131ran bir ba\u015fka klinik ara\u015ft\u0131rma \u00e7al\u0131\u015fmas\u0131n\u0131 temsil etmektedir. Gelecek klinik veriler, STM-01&#039;in klinik \u00f6ncesi potansiyelini DMD ile ya\u015fayan insanlar i\u00e7in anlaml\u0131 faydalara d\u00f6n\u00fc\u015ft\u00fcr\u00fcp d\u00f6n\u00fc\u015ft\u00fcremeyece\u011fini anlamak a\u00e7\u0131s\u0131ndan \u00f6nemli olacakt\u0131r.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Daha Fazlas\u0131n\u0131 Ke\u015ffedin<\/strong>:&nbsp;<a href=\"https:\/\/dmdwarrior.com\/clinical-trials\/map\/\" target=\"_blank\" rel=\"noopener\">Duchenne Klinik Ara\u015ft\u0131rma Yerleri Haritas\u0131<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Secretome Therapeutics has announced the start of THRIVE-2, a Phase 2 clinical study evaluating its investigational therapy STM-01 in people living with Duchenne muscular dystrophy (DMD). The study is now open for enrollment, with the first participant expected to enroll soon. What Is THRIVE-2? THRIVE-2 is designed as a multicenter, multi-dose, open-label Phase 2 clinical [&hellip;]<\/p>\n","protected":false},"author":10,"featured_media":8822,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[27],"tags":[362,914,920,919,921],"class_list":["post-8819","post","type-post","status-publish","format-standard","has-post-thumbnail","category-research","tag-dmd-cardiomyopathy","tag-phase-2","tag-secretome-therapeutics","tag-stm-01","tag-thrive-2"],"subtitle":"Yeni bir klinik \u00e7al\u0131\u015fma, STM-01'i Duchenne kas distrofisi alan\u0131nda yeniden g\u00fcndeme getiriyor. Secretome Therapeutics, DMD'de iltihaplanma ve fibrozisi hedefleyen yeni bir yakla\u015f\u0131m\u0131 ara\u015ft\u0131ran Faz 2 \u00e7al\u0131\u015fmas\u0131 olan THRIVE-2'yi ba\u015flatt\u0131.","_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/8819","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/users\/10"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/comments?post=8819"}],"version-history":[{"count":3,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/8819\/revisions"}],"predecessor-version":[{"id":8824,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/8819\/revisions\/8824"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/media\/8822"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/media?parent=8819"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/categories?post=8819"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/tags?post=8819"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}